M Dubar
Overview
Explore the profile of M Dubar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simon T, Bhatt D, Bergougnan L, Farenc C, Pearson K, Perrin L, et al.
Clin Pharmacol Ther
. 2011 Jul;
90(2):287-95.
PMID: 21716274
A double-blind crossover study was conducted in four CYP2C19 genotype-defined metabolizer groups to assess whether increase in clopidogrel dosing can overcome reduced pharmacodynamic response in CYP2C19 poor metabolizers (PMs). Ten...
2.
Angiolillo D, Gibson C, Cheng S, Ollier C, Nicolas O, Bergougnan L, et al.
Clin Pharmacol Ther
. 2010 Sep;
89(1):65-74.
PMID: 20844485
Four randomized, placebo-controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between clopidogrel (300-mg loading dose/75-mg/day maintenance dose) and the proton-pump inhibitor (PPI) omeprazole...
3.
Osende J, Shimbo D, Fuster V, Dubar M, Badimon J
J Thromb Haemost
. 2004 Mar;
2(3):492-8.
PMID: 15009468
Platelet activation and thrombus formation play a critical role in the onset of acute coronary syndromes. Thromboxane A2 (TxA2) is among the different chemical modulators released by activated platelets. TxA2...
4.
Gaussem P, Dubar M, Le Bonniec B, Jochemsen R, Aiach M
Br J Clin Pharmacol
. 2002 Feb;
53(2):147-54.
PMID: 11851638
Aims: We conducted a phase I placebo-controlled trial with two i.v. doses (0.5 mg h-1 and 3 mg h-1) of S 18326, a selective thrombin inhibitor that interacts with the...
5.
Penicaud L, Berthault M, Morin J, Dubar M, Ktorza A, Ferre P
J Hypertens Suppl
. 1998 Sep;
16(3):S45-9.
PMID: 9747910
Objective: The aim of this study was to determine the effects of rilmenidine (an antihypertensive drug that lowers blood pressure by decreasing sympathetic outflow) in an animal model of hypertension...
6.
Boucher M, Dubar M, Chapuy E, Chassaing C
J Auton Pharmacol
. 1997 Apr;
17(2):87-90.
PMID: 9234078
1. The cardiac vagal effects of rilmenidine (5 micrograms kg-1 min-1) and clonidine (0.5 micrograms kg-1 min-1) were studied in chloralose anaesthetized dogs. 2. Rilmenidine and clonidine progressively reduced the...
7.
Berthault M, Morin J, Dubar M, Ktorza A, Ferre P, Penicaud L
Arch Mal Coeur Vaiss
. 1996 Aug;
89(8):1103-6.
PMID: 8949387
This study was aimed to determine the effects of rilmenidine, an hypertensive drug, in an animal model of hypertension associated with insulin resistance, i.e. rats fed on a high fructose...
8.
Boucher M, Dubar M, Chapuy E, Chassaing C
J Auton Pharmacol
. 1996 Feb;
16(1):13-20.
PMID: 8736426
1. The cardiac chronotropic effects of rilmenidine (10-100 micrograms kg-1) and clonidine (1-10 micrograms kg-1) were studied in conscious dogs with chronic atrioventricular block. 2. Rilmenidine and clonidine initially (<...
9.
10.
Boucher M, Dubar M, Chassaing C, Vivet P, DUCHENE-MARULLAZ P
Life Sci
. 1994 Jan;
54(22):PL381-7.
PMID: 8177003
The cardiac electrophysiological effects of rilmenidine, a novel antihypertensive agent, and clonidine were studied in the conscious dog. Sinus rate, corrected sinus recovery time (CSRT) and Wenckebach point (WP) were...